Literature DB >> 16621157

Proenkephalin A 119-159, a stable proenkephalin A precursor fragment identified in human circulation.

A Ernst1, J Köhrle, A Bergmann.   

Abstract

In this report, we describe a newly developed sandwich immunoassay using antibodies against the proenkephalin A 119-159 peptide (PENK A 119-159). PENK A 119-159 immunoreactivity was detectable in the circulation of human blood donors and in cerebrospinal fluid (CSF) of patients without a neurologic disorder. The concentration was about 100 times higher in CSF than in serum. Analytical reversed phase HPLC revealed that PENK A 119-159 is the main immunoreactivity in human circulation and CSF. Moreover, PENK A 119-159 is stable in vitro for at least 48 h at room temperature as compared to the low stability of the peptides methionine- and leucine-enkephalin. This suggests the use of PENK A 119-159 measurement as surrogate molecule for the release of the mature peptides derived from proenkephalin A.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16621157     DOI: 10.1016/j.peptides.2006.03.008

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  18 in total

Review 1.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

2.  High Level of Fasting Plasma Proenkephalin-A Predicts Deterioration of Kidney Function and Incidence of CKD.

Authors:  Christina-Alexandra Schulz; Anders Christensson; Ulrika Ericson; Peter Almgren; George Hindy; Peter M Nilsson; Joachim Struck; Andreas Bergmann; Olle Melander; Marju Orho-Melander
Journal:  J Am Soc Nephrol       Date:  2016-07-08       Impact factor: 10.121

3.  Laboratory exposure of Oreochromis niloticus to crude microcystins (containing microcystin-LR) extracted from Egyptian locally isolated strain (Microcystis aeruginosa Kützing): biological and biochemical studies.

Authors:  Mai D Ibrahem; Hanan M Khairy; Marwa A Ibrahim
Journal:  Fish Physiol Biochem       Date:  2011-11-18       Impact factor: 2.794

4.  Plasma Pro-Enkephalin A and Ischemic Stroke Risk: The Reasons for Geographic and Racial Differences in Stroke Cohort.

Authors:  Samuel Ap Short; Katherine Wilkinson; D Leann Long; Suzanne Judd; Janin Schulte; Brett M Kissela; George Howard; Mary Cushman
Journal:  J Stroke Cerebrovasc Dis       Date:  2021-12-09       Impact factor: 2.136

5.  Diagnostic and short-term prognostic utility of plasma pro-enkephalin (pro-ENK) for acute kidney injury in patients admitted with sepsis in the emergency department.

Authors:  Rossella Marino; Joachim Struck; Oliver Hartmann; Alan S Maisel; Miriam Rehfeldt; Laura Magrini; Olle Melander; Andreas Bergmann; Salvatore Di Somma
Journal:  J Nephrol       Date:  2014-12-09       Impact factor: 3.902

6.  Pro-Enkephalin and its association with renal function in Middle Eastern immigrants and native Swedes.

Authors:  Christopher Nilsson; Anders Christensson; Peter M Nilsson; Olle Melander; Louise Bennet
Journal:  Scand J Clin Lab Invest       Date:  2021-09-28       Impact factor: 1.713

7.  Plasma Proenkephalin and Poor Long-Term Outcome in Renal Transplant Recipients.

Authors:  Lyanne M Kieneker; Oliver Hartmann; Joachim Struck; Andreas Bergmann; Ron T Gansevoort; Michel M Joosten; Else van den Berg; Rudolf A de Boer; Stephan J L Bakker
Journal:  Transplant Direct       Date:  2017-07-07

8.  Plasma proenkephalin A 119-159 on intensive care unit admission is a predictor of organ failure and 30-day mortality.

Authors:  Attila Frigyesi; Lisa Boström; Maria Lengquist; Patrik Johnsson; Oscar H M Lundberg; Martin Spångfors; Martin Annborn; Tobias Cronberg; Niklas Nielsen; Helena Levin; Hans Friberg
Journal:  Intensive Care Med Exp       Date:  2021-07-19

9.  Basal Plasma Levels of Copeptin are Elevated in Inactive Inflammatory Bowel Disease after Bowel Resection.

Authors:  Bodil Ohlsson; Olle Melander
Journal:  Drug Target Insights       Date:  2015-07-13

10.  Serum Proenkephalin A Levels and Mortality After Long-Term Follow-Up in Patients with Type 2 Diabetes Mellitus (ZODIAC-32).

Authors:  Kornelis J J van Hateren; Gijs W D Landman; Jarinke F H Arnold; Hanneke Joosten; Klaas H Groenier; Gerjan J Navis; Andrea Sparwasser; Stephan J L Bakker; Henk J G Bilo; Nanne Kleefstra
Journal:  PLoS One       Date:  2015-07-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.